Trublood® is a revolutionary, blood-based cancer detection and triaging solution designed to identify the presence of malignancy in suspected cases of solid organ and brain cancers. By analyzing live circulating tumor cells (CTCs) isolated from a simple blood sample, Trublood® offers a safe, accurate, and non-invasive alternative to conventional tissue biopsies. Clinically validated on more than 40,000 samples through CTRI-registered clinical trials, Trublood® provides clinicians with a powerful tool to support early diagnostic decision-making while minimizing the risks, discomfort, and limitations associated with invasive biopsy procedures.
Enabling Safer, Faster, and More Accessible Cancer Assessment
Detect cancer-associated signals through a simple blood draw without invasive procedures
Clinically validated with high sensitivity and specificity for reliable triaging
Analyze live circulating tumor cells representing active disease biology
Blood samples can be collected without hospitalization or anesthesia
Advanced Circulating Tumor Cell Analysis for Precision Diagnostics
Isolation and analysis of live circulating tumor cells (CTCs) and clusters from blood
Captures signals from active disease sites across the body
Overall sensitivity of 99.8% and specificity of 95.4%
Testing can be repeated whenever clinically required
Actionable Insights Across the Diagnostic Journey
Support evaluation of individuals advised invasive biopsy for suspected malignancy.
Provide safer assessment when tissue biopsy is difficult, risky, or inconclusive.
Help rule out new primary malignancies in suspected metastatic relapse cases.
Analyze live tumor-associated signals representing ongoing cancer activity.
Enable repeat testing without the limitations of invasive procedures.
Patients advised tissue biopsy to evaluate possible malignancy.
Cases where prior invasive biopsy findings are unclear or inconsistent.
Individuals where tissue biopsy may pose procedural risks.
Cases requiring evaluation for possible new primary tumors.
Patients preferring a blood-based diagnostic approach.
Peripheral blood sample collection without hospitalization or anesthesia.
Sensitive isolation of live circulating tumor cells and clusters from blood.
Extensive immunocytochemistry-based evaluation of tumor-associated cells.
Analysis of active tumor-derived cellular signals across disease sites.
Generation of actionable diagnostic insights to guide further management.
Detect the presence of cancer-associated circulating tumor cells.
Provide insights based on live tumor-derived cellular signals.
Assist clinicians in determining the need for invasive biopsy procedures.
Capture tumor signals from multiple active disease locations.
Enable cancer investigation through a minimally invasive approach.